Acutus Medical, Inc. (AFIB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acutus Medical, Inc. (AFIB) trades at $0.00 with AI Score 44/100 (Grade C). Acutus Medical, Inc. is an arrhythmia management company specializing in catheter-based ablation tools for treating various arrhythmias. Market cap: $2,991, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for AFIB: AFIB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AFIB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AFIB: the 1 perspectives are evenly split.
How is this calculated? →Acutus Medical, Inc. (AFIB) Healthcare & Pipeline Overview
Acutus Medical, Inc. is a pioneering arrhythmia management company focused on developing advanced catheter-based solutions for the diagnosis and treatment of cardiac arrhythmias, leveraging innovative mapping technologies to enhance patient outcomes in electrophysiology.
What Is the Investment Thesis for AFIB?
Acutus Medical, Inc. operates in a critical segment of the healthcare industry, focusing on cardiac electrophysiology solutions that address the growing prevalence of arrhythmias. The company’s innovative product offerings, including advanced mapping systems and catheter-based tools, position it well for future growth. Key value drivers include the increasing demand for minimally invasive procedures, the expansion of their product portfolio, and potential partnerships with healthcare providers. However, the company faces significant risks, including financial distress as indicated by a market capitalization of only $9K and a negative profit margin of -47.4%. Monitoring Acutus Medical's ability to secure additional funding and regain compliance with listing requirements will be crucial for its future viability and growth potential.
Based on FMP financials and quantitative analysis
AFIB Key Highlights
- Market Cap of 3K indicating significant financial distress.
- Profit Margin of -47.4%, reflecting ongoing challenges in profitability.
- Gross Margin of 5.0%, which is considerably low compared to industry standards.
- Beta of -1.19, suggesting inverse volatility relative to the market.
- No dividend yield, indicating a focus on reinvestment rather than shareholder returns.
Who Are AFIB's Competitors?
AFIB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABMD Abiomed, Inc. | $381.02 | +0.00% | $17.18B | 60 |
| BAX Baxter International Inc. | $22.45 | -0.88% | $11.59B | 52 |
| MDT Medtronic plc | $83.06 | -0.16% | 107B | 77 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AFIB's Key Strengths?
- Innovative product offerings in the arrhythmia management space.
- Strong focus on research and development to drive product enhancement.
- Expertise in catheter-based technologies for cardiac procedures.
What Are AFIB's Weaknesses?
- Significant financial distress indicated by low market capitalization.
- Negative profit margin reflecting ongoing operational challenges.
- Limited brand recognition compared to larger competitors.
What Could Drive AFIB Stock Higher?
- Potential partnerships with healthcare providers to enhance product adoption.
- Development of innovative mapping systems for complex arrhythmia cases.
- Focus on securing additional funding to support operational stability.
What Are the Key Risks for AFIB?
- Financial-distress signal — its Altman Z-Score of -28.39 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $5.6M recently.
- Financial distress due to extremely low market capitalization.
- Regulatory challenges in obtaining necessary approvals for new products.
- Competition from established medical device companies impacting market share.
What Are the Growth Opportunities for AFIB?
- Growth opportunity 1: The global electrophysiology market is expected to reach approximately $9 billion by 2027, driven by advancements in catheter-based technologies and increasing demand for minimally invasive procedures. Acutus Medical's innovative mapping systems and ablation tools position the company to capture a significant share of this expanding market, particularly as healthcare providers seek more effective solutions for complex arrhythmias.
- Growth opportunity 2: Expansion into international markets presents a substantial growth opportunity for Acutus Medical. As healthcare systems worldwide increasingly adopt advanced cardiac care technologies, the company can leverage its innovative product offerings to penetrate new geographic regions, thereby increasing its customer base and revenue streams. Targeting markets in Europe and Asia could yield significant returns over the next five years.
- Growth opportunity 3: The rise in telemedicine and remote patient monitoring is reshaping the healthcare landscape. Acutus Medical can capitalize on this trend by integrating its products with telehealth solutions, allowing for remote diagnostics and monitoring of patients with arrhythmias. This integration could enhance patient engagement and adherence to treatment plans, driving adoption of Acutus's technologies.
- Growth opportunity 4: Strategic partnerships with hospitals and healthcare providers can enhance Acutus Medical's market presence and credibility. Collaborating with leading institutions to conduct clinical trials and gather real-world evidence on the efficacy of its products can bolster the company's reputation and facilitate broader adoption of its technologies in clinical practice.
- Growth opportunity 5: Continuous innovation in product development is essential for sustaining competitive advantage. Acutus Medical can invest in research and development to enhance its existing product portfolio and introduce new solutions that address unmet clinical needs in arrhythmia management. This focus on innovation can drive long-term growth and solidify the company's position in the market.
What Opportunities Does AFIB Have?
- Growing global market for electrophysiology solutions.
- Expansion into international markets to increase revenue potential.
- Integration of telehealth solutions with existing products for enhanced patient care.
What Threats Does AFIB Face?
- Intense competition from established medical device companies.
- Regulatory challenges and compliance requirements in the healthcare sector.
- Potential for market volatility impacting funding and investment.
What Are AFIB's Competitive Advantages?
- Innovative product portfolio that addresses complex arrhythmia cases.
- Strong focus on research and development to stay ahead of competitors.
- Established relationships with healthcare providers for product validation and adoption.
What Does AFIB Do?
Founded in 2011 and headquartered in Carlsbad, California, Acutus Medical, Inc. is an arrhythmia management company dedicated to revolutionizing the treatment of cardiac arrhythmias through its innovative catheter-based ablation tools. The company has developed a comprehensive product portfolio that includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, and both conventional and contact force ablation catheters. Additionally, Acutus provides mapping and imaging consoles, accessories, and supporting algorithms and software programs that enhance the efficacy and safety of electrophysiology procedures. Acutus Medical has positioned itself as a key player in the cardiac electrophysiology market, focusing on advanced solutions that cater to the growing demand for effective arrhythmia treatment options. Despite facing challenges related to financial performance and market capitalization, the company continues to focus on innovation and product development to improve patient care and outcomes in the arrhythmia management space. With a dedicated workforce of 85 employees, Acutus Medical is committed to expanding its reach both in the United States and internationally, aiming to address the increasing prevalence of arrhythmias and the need for effective treatment solutions.
What Products and Services Does AFIB Offer?
- Design and manufacture catheter-based tools for arrhythmia treatment.
- Develop advanced mapping systems for diagnosing cardiac arrhythmias.
- Market a range of ablation catheters and accessories.
- Provide software programs and algorithms to support electrophysiology procedures.
- Focus on innovation to improve patient outcomes in cardiac care.
- Operate both domestically in the U.S. and internationally.
How Does AFIB Make Money?
- Generate revenue through the sale of medical devices and tools for arrhythmia management.
- Offer innovative solutions that cater to the needs of electrophysiology specialists.
- Leverage partnerships with healthcare providers for product adoption and clinical validation.
- Invest in research and development to enhance product offerings and maintain competitive edge.
What Industry Does AFIB Operate In?
The medical devices industry, particularly in the cardiac sector, is experiencing robust growth driven by an aging population and increasing prevalence of cardiovascular diseases. The global electrophysiology market is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of over 10% through the next several years. Acutus Medical, Inc. operates in a competitive landscape that includes established players and emerging companies, necessitating continuous innovation and differentiation to capture market share and meet evolving healthcare needs.
Who Are AFIB's Key Customers?
- Electrophysiologists and cardiologists specializing in arrhythmia management.
- Hospitals and healthcare systems seeking advanced cardiac care solutions.
- Medical device distributors and suppliers in the healthcare sector.
Net sellingInsider Activity
The most recent 12 insider filings for Acutus Medical, Inc. break down as 12 sales and 0 purchases. On net that is roughly 2.2M shares disposed (about $5.6M), a signal worth weighing alongside the fundamentals.
FY2026 estForward Outlook
Wall Street analysts project Acutus Medical, Inc. revenue of about $98.8M for fiscal 2026, with EPS near $-1.35.
F-Score 3/9Financial Health
Acutus Medical, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.39 places it in the distress zone, a signal of elevated financial risk.
ROE 153%Key Financial Metrics
Return on equity for Acutus Medical, Inc. stands at 153.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.3%, showing how much profit it generates from its asset base. A current ratio of 2.06 indicates the company holds enough short-term assets to cover its near-term obligations.
Acutus Medical, Inc. (AFIB) Valuation Context
Valued at 3K, AFIB is classified as a micro-cap stock. Relative to its peer group, AFIB's quantitative score of 44/100 is below the peer average of 67/100.
AFIB Revenue & Earnings Trend
In Q4 2024, AFIB generated $7.1M in top-line revenue, marking a sequential increase of 35.6%. The company recorded a net loss of $1.4M, with diluted EPS of $-0.05. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, AFIB averaged $-0.08 in diluted EPS.
Company Profile
Acutus Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO Takeo Mukai. AFIB has traded publicly since 2020.
AFIB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Acutus Medical's long-term prospects.
- Positive community sentiment indicates growing belief in the company's technology.
- The market seems to be recognizing the potential of Acutus Medical's innovative solutions in cardiac mapping.
- Increased social media mentions suggest growing brand awareness and potential customer interest.
Bear Case
- Insider buying could be strategic rather than indicative of genuine confidence; further investigation needed.
- Community sentiment can be easily swayed by short-term trends and may not reflect true fundamentals.
- Market perception might be overly optimistic, overlooking potential challenges in adoption and competition.
- Negative comments within the broader social media buzz could signal underlying concerns about product efficacy.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $7M | -$1M | -$0.05 |
| Q3 2024 | $5M | -$6M | -$0.19 |
| Q2 2024 | $4M | -$914,000 | -$0.03 |
| Q1 2024 | $4M | -$2M | -$0.05 |
Based on FMP financials and quantitative analysis
AFIB Latest News
No recent news available for AFIB.
AFIB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AFIB.
Price Targets
Wall Street price target analysis for AFIB.
AFIB MoonshotScore
What does this score mean?
The MoonshotScore rates AFIB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Takeo Mukai
CEO
Takeo Mukai has extensive experience in the medical device industry, having held various leadership roles in product development and commercialization. He has a strong educational background in engineering and business, which supports his strategic vision for Acutus Medical. Mukai's leadership is characterized by a commitment to innovation and improving patient outcomes through advanced medical technologies.
Track Record: Under Takeo Mukai's leadership, Acutus Medical has focused on developing cutting-edge solutions for cardiac arrhythmias, enhancing the company's product portfolio and market presence. His strategic decisions have aimed at positioning the company for future growth despite current financial challenges.
AFIB OTC Market Information
The OTC Other tier includes companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier is generally characterized by lower trading volumes and less stringent reporting standards, which can lead to increased risks for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Low market capitalization indicating financial instability.
- Limited trading volume leading to liquidity concerns.
- Regulatory scrutiny associated with OTC market listings.
- Verify the company's financial health and recent performance metrics.
- Assess the competitive landscape and market positioning.
- Review the regulatory compliance status and any pending approvals.
- Investigate management's track record and strategic vision.
- Monitor news and developments that could impact business operations.
- Incorporation in 2011 and established presence in the medical device industry.
- Product portfolio designed for a growing healthcare market.
- Commitment to innovation and improving patient outcomes.
AFIB Healthcare Stock FAQ
What does Acutus Medical, Inc. do?
Acutus Medical, Inc. specializes in the design and manufacture of advanced catheter-based tools for the treatment of cardiac arrhythmias. Their product portfolio includes diagnostic and mapping catheters, ablation catheters, and supporting software solutions, aimed at improving patient outcomes in electrophysiology.
How does Acutus Medical, Inc. navigate regulatory approval processes?
Acutus Medical, Inc. follows a comprehensive regulatory strategy to ensure compliance with FDA and international standards for medical devices. This includes rigorous testing and validation of their products, as well as maintaining open communication with regulatory bodies to facilitate timely approvals.
What are the main risks for AFIB?
Acutus Medical, Inc. faces several risks, including significant financial distress indicated by a low market capitalization, which raises concerns about operational viability. Additionally, the company must navigate regulatory challenges associated with product approvals and face intense competition from larger, established medical device firms that could impact market share.
What are the key factors to evaluate for AFIB?
Acutus Medical, Inc. (AFIB) holds an AI score of 44/100 (low). Not financial advice.
How frequently does AFIB data refresh on this page?
AFIB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AFIB's recent stock price performance?
Acutus Medical, Inc. (AFIB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings in the arrhythmia management space. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AFIB overvalued or undervalued right now?
Valuing Acutus Medical, Inc. (AFIB) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AFIB?
Before investing in Acutus Medical, Inc. (AFIB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial performance may not be fully disclosed due to OTC listing status.